X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Tivdak (tisotumab vedotin) is an antibody-drug conjugate that acts as coagulation factor III binding agent & tubulin inhibitor. It is approved for the treatment of recurrent or metastatic cervical cancer.
Lead Product(s): Tisotumab Vedotin
Therapeutic Area: Oncology Product Name: Tivdak
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Genmab
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2024
Details:
Tivdak (tisotumab vedotin-tftv) is an antibody-drug conjugate that acts as coagulation factor III binding agent. It is being evaluated for the treatment of recurrent or metastatic cervical cancer.
Lead Product(s): Tisotumab Vedotin
Therapeutic Area: Oncology Product Name: Tivdak
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2024
Details:
Tivdak (tisotumab vedotin-tftv) is a tissue factor (TF)-directed antibody drug conjugate. It is approved by USFDA for the treatment of cervical cancer.
Lead Product(s): Tisotumab Vedotin
Therapeutic Area: Oncology Product Name: Tivdak
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2024
Details:
Tivdak (tisotumab vedotin-tftv) is an antibody-drug conjugate (ADC) composed of Genmab’s human monoclonal antibody directed to tissue factor (TF) and Pfizer’s ADC technology. It is being evaluated in phase 3 studies for the treatment of recurrent or metastatic cervical cancer.
Lead Product(s): Tisotumab Vedotin
Therapeutic Area: Oncology Product Name: Tivdak
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Details:
Tivdak (tisotumab vedotin) is an antibody-drug conjugate, which is investigating in phase III and met its primary endpoint of overall survival for recurrent or metastatic cervical cancer compared to chemotherapy.
Lead Product(s): Tisotumab Vedotin
Therapeutic Area: Oncology Product Name: Tivdak
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Seagen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2023
Details:
TIVDAK (tisotumab vedotin) is an antibody-drug conjugate, which is investigating in phase III and met its primary endpoint of overall survival for recurrent or metastatic cervical cancer compared to chemotherapy.
Lead Product(s): Tisotumab Vedotin
Therapeutic Area: Oncology Product Name: Tivdak
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Seagen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 04, 2023
Details:
Interim results of tisotumab vedotin (Tivdak) plus pembrolizumab from Phase 1b/2 innovaTV 205 trial, showing 41% objective response rate in first-line patients with recurrent or metastatic cervical cancer (r/mCC).
Lead Product(s): Tisotumab Vedotin,Pembrolizumab
Therapeutic Area: Oncology Product Name: Tivdak
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Seagen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Tisotumab vedotin-tftv (TIVDAK®) is an antibody-drug conjugate (ADC) composed of Genmab’s human monoclonal antibody directed to tissue factor and Seagen’s ADC technology that utilizes protease-cleavable linker that covalently attaches MMAE to antibody.
Lead Product(s): Tisotumab Vedotin,Pembrolizumab
Therapeutic Area: Oncology Product Name: Tivdak
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Seagen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Data from innovaTV 207 phase 2 trial of TIVDAK (tisotumab vedotin), an antibody-drug conjugate, demonstrated manageable safety profile and promising preliminary antitumor activity, also met primary endpoint of confirmed ORR per investigator, achieved by 16 percent of patients.
Lead Product(s): Tisotumab Vedotin,Pembrolizumab,Carboplatin
Therapeutic Area: Oncology Product Name: Tivdak
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Seagen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2022
Details:
The innovaTV 205 trial of tisotumab vedotin (TV) is designed to evaluate the safety and efficacy of TV as monotherapy and in combination with chemotherapy and other agents in recurrent or metastatic cervical cancer.
Lead Product(s): Tisotumab Vedotin,Bevacizumab
Therapeutic Area: Oncology Product Name: HuMax-TF-ADC
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2021
Details:
The submission is based on the results of the innovaTV 204 pivotal phase 2 single-arm clinical trial evaluating tisotumab vedotin as monotherapy in this setting.
Lead Product(s): Tisotumab Vedotin
Therapeutic Area: Oncology Product Name: GCT1015-04
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Seagen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2021
Details:
Data from the innovaTV 204 pivotal phase 2, single-arm clinical trial evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent/metastatic cervical cancer shows that Tisotumab vedotin has meaningful clinical activity in curbing the disease.
Lead Product(s): Tisotumab Vedotin
Therapeutic Area: Oncology Product Name: HuMax-TF-ADC
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Genmab
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
Details:
Results from the phase 2 innovaTV 204 study evaluating tisotumab vedotin in patients with recurrent or metastatic cervical cancer will be presented as a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
Lead Product(s): Tisotumab Vedotin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
Details:
Twelve abstracts, including a late-breaking abstract accepted for oral presentation featuring data from the positive tisotumab vedotin phase 2 innovaTV 204 clinical trial in recurrent or metastatic cervical cancer will be presented at ESMO Virtual Congress 2020.
Lead Product(s): Tisotumab Vedotin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
Details:
Results from the trial showed a 24 percent confirmed objective response rate (ORR) by independent central review [95% Confidence Interval: 15.9%-33.3%] with a median duration of response (DOR) of 8.3 months.
Lead Product(s): Tisotumab Vedotin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2020
Details:
Results from innovaTV 204 evaluating tisotumab vedotin showed that a 24 percent confirmed objective response rate (ORR) by independent central review (95% Confidence Interval: 15.9% - 33.3%) with a median duration of response (DOR) of 8.3 months.
Lead Product(s): Tisotumab Vedotin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
